These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10571516)

  • 21. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
    Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
    Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Contribution of cell cycle and DNA content study by flow cytometry in the prognosis of superficial bladder cancer: Tunisian experience].
    Bounemra-Benghanem A; Amri MA; Rammeh-Rommani S; Chebil M; Zermani R; Ben Jilani S; Jenhani F
    Ann Biol Clin (Paris); 2007; 65(1):41-9. PubMed ID: 17264038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome.
    Sgambato A; Migaldi M; Faraglia B; De Aloysio G; Ferrari P; Ardito R; De Gaetani C; Capelli G; Cittadini A; Trentini GP
    Int J Cancer; 2002 Feb; 97(5):671-8. PubMed ID: 11807796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
    Wolf HK; Stöber C; Hohenfellner R; Leissner J
    Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis of MiB1 and p53 expression in human bladder tumors and their correlation with cancer progression.
    Pfister C; Buzelin F; Casse C; Bochereau G; Buzelin JM; Bouchot O
    Eur Urol; 1998; 33(3):278-84. PubMed ID: 9555552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of MIB-1, mitotic index and S-phase fraction as indicators of cell proliferation in superficial bladder cancer. Finnbladder Group.
    Liukkonen TJ; Lipponen PK; Helle M; Haapasalo HK; Nordling S; Rajala P
    Urol Res; 1996; 24(1):61-6. PubMed ID: 8966844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
    Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
    Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of different p16 immunostaining methods and the prognostic role of p16/Ki-67 combined expression in non-muscle invasive bladder cancers.
    Özyalvaçli G; Özyalvaçli ME; Astarci HM; Boran Ç; Yeşil C; Üyetürk U; Aktaș G
    Pol J Pathol; 2015 Mar; 66(1):57-66. PubMed ID: 26017881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors.
    Stavropoulos NE; Filliadis I; Ioachim E; Michael M; Mermiga E; Hastazeris K; Nseyo UO
    Int Urol Nephrol; 2001; 33(3):479-83. PubMed ID: 12230276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.
    Otto W; Denzinger S; Fritsche HM; Burger M; Rößler W; Bertz S; May M; Hartmann A; Hofstädter F; Wieland WF; Eder F
    Clin Genitourin Cancer; 2013 Dec; 11(4):537-44. PubMed ID: 23850551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer.
    Nonomura N; Nakai Y; Nakayama M; Inoue H; Nishimura K; Hatanaka E; Arima R; Kishimoto T; Miki T; Kuroda H; Okuyama A
    Int J Clin Oncol; 2006 Aug; 11(4):297-302. PubMed ID: 16937303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deoxyribonucleic acid content and survival rates of patients with transitional cell carcinoma of the bladder.
    al-Abadi H; Nagel R
    J Urol; 1994 Jan; 151(1):37-42. PubMed ID: 8254829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma.
    Pinto AE; André S; Pereira T; Nóbrega S; Soares J
    J Clin Pathol; 2001 Jul; 54(7):543-9. PubMed ID: 11429427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma.
    Gelb AB; Sudilovsky D; Wu CD; Weiss LM; Medeiros LJ
    Cancer; 1997 Nov; 80(9):1768-75. PubMed ID: 9351546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.